577 related articles for article (PubMed ID: 15554934)
1. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
[TBL] [Abstract][Full Text] [Related]
2. Effect of hemodialysis membrane type on parathyroid hormone removal.
Kudlac H; Fielding AM; Williams AJ
Miner Electrolyte Metab; 1994; 20(5):245-9. PubMed ID: 7700210
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone.
Makar SH; Sawires HK; Farid TM; Ali WM; Schaalan M
Iran J Kidney Dis; 2010 Oct; 4(4):327-32. PubMed ID: 20852376
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein in patients on chronic hemodialysis with different techniques and different membranes.
Panichi V; Rizza GM; Taccola D; Paoletti S; Mantuano E; Migliori M; Frangioni S; Filippi C; Carpi A
Biomed Pharmacother; 2006 Jan; 60(1):14-7. PubMed ID: 16330177
[TBL] [Abstract][Full Text] [Related]
6. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism.
De Francisco AL; Amado JA; Prieto M; Alcalde G; Sanz de Castro S; Ruiz JC; Morales P; Arias M
Nephron; 1994; 66(4):442-6. PubMed ID: 8015649
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of serum, outflow dialysate and adsorbed protein onto dialysis membranes (polysulfone and pmma) during hemodialysis treatment using SELDI-TOF-MS.
Ishikawa I; Chikazawa Y; Sato K; Nakagawa M; Imamura H; Hayama S; Yamaya H; Asaka M; Tomosugi N; Yokoyama H; Matsumoto K
Am J Nephrol; 2006; 26(4):372-80. PubMed ID: 16873993
[TBL] [Abstract][Full Text] [Related]
8. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
9. Hemodiafiltration--a new treatment option for hyperphosphatemia in hemodialysis patients.
Zehnder C; Gutzwiller JP; Renggli K
Clin Nephrol; 1999 Sep; 52(3):152-9. PubMed ID: 10499310
[TBL] [Abstract][Full Text] [Related]
10. High- and low-flux acetate-free biofiltration: experimental assessment of calcium mass balance and intact parathyroid hormone behaviour.
de Vincenzi A; Bellazzi RG; Santagostino M; Gazo A; Romanini D; Nai M; Maretti L; Ornati G; Bellazzi R
Nephrol Dial Transplant; 1994; 9(9):1305-9. PubMed ID: 7816296
[TBL] [Abstract][Full Text] [Related]
11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
12. Comment on middle molecule removal in low-flux polysulfone dialyzers: impact of flows and surface area on whole-body and dialyzer clearances.
Polaschegg HD
Hemodial Int; 2006 Apr; 10(2):215-6; author reply 216. PubMed ID: 16623678
[No Abstract] [Full Text] [Related]
13. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: a randomized, single-blinded, controlled clinical trial.
Kerr PG; Sutherland WH; de Jong S; Vaithalingham I; Williams SM; Walker RJ
Am J Kidney Dis; 2007 Apr; 49(4):533-9. PubMed ID: 17386321
[TBL] [Abstract][Full Text] [Related]
14. Clinical characterization of Dicea a new cellulose membrane for haemodialysis.
Hoenich NA; Woffindin C; Cox PJ; Goldfinch M; Roberts SJ
Clin Nephrol; 1997 Oct; 48(4):253-9. PubMed ID: 9352161
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
[TBL] [Abstract][Full Text] [Related]
16. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic influence of hemodialysis according to the membrane used on phagocytic function of neutrophils and monocytes and pro-inflammatory cytokines production in chronic renal failure patients.
Muniz-Junqueira MI; Braga Lopes C; Magalhães CA; Schleicher CC; Veiga JP
Life Sci; 2005 Nov; 77(25):3141-55. PubMed ID: 16005905
[TBL] [Abstract][Full Text] [Related]
18. Enhanced long-term reduction of plasma leptin concentrations by super-flux polysulfone dialysers.
van Tellingen A; Grooteman MP; Schoorl M; ter Wee PM; Bartels PC; Schoorl M; van der Ploeg T; Nubé MJ
Nephrol Dial Transplant; 2004 May; 19(5):1198-203. PubMed ID: 14993491
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
Hwang JC; Chen CA; Wang CT; Chen HC
Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144
[TBL] [Abstract][Full Text] [Related]
20. Changes in parathyroid hormone during haemodialysis sessions with two different dialysis membranes: specific adsorption of intact parathyroid hormone.
Valat C; Pengloan J; Blanchier D; Bagros P; Besnard JC
Nucl Med Commun; 1993 Feb; 14(2):130-6. PubMed ID: 8429992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
